...
首页> 外文期刊>Bulletin of the Korean Chemical Society >Novel Hybrid Molecules of Epinastine and Mefenamic Acid for Bioactive Assessment as Potential Anti‐inflammatory Agents
【24h】

Novel Hybrid Molecules of Epinastine and Mefenamic Acid for Bioactive Assessment as Potential Anti‐inflammatory Agents

机译:用于生物活性评估的新型杂交分子和梅青酸作为潜在的抗炎剂

获取原文
           

摘要

A set of novel epinastine (1) and mefenamic acid (2) hybrids (3–7) tethered via amide bond were designed and synthesized with the artistry of molecular hybridization. Then their inhibitory effect on nitric oxide (NO) production in LPS‐induced RAW‐264.7 macrophages and the expression levels of prostaglandin (PG) synthesis regulatory genes were evaluated in vitro. All the hybrids were found to have remarkable NO production inhibitory potential with IC50 values ranging in between 27.69?±?3.06 and 40.19?±?5.52?μM without notable cytotoxicity (CC50?≥?100?μM) except 6. Comparing the inhibitory effects, cytotoxicity and in vitro efficacy index (iEI), 4 (IC50 = 32.09?±?4.04?μM; iEI = 6.23) and 7 (IC50 = 27.69?±?3.06?μM; iEI = 6.40) were better suited than other hybrids as well as their parent compounds EH and MA. This outcome was further harmonized with the reduced microsomal prostaglandin E synthase‐1 expression and unaltered housekeeping COX‐1 expression by hybrids 4 and 7 treatment. Altogether, our findings signify that hybrids 4 and 7 may serve as platforms for continued investigations for the development of more efficient anti‐inflammatory agents.
机译:通过酰胺键合的一组新型卓越素(1)和Mefenamic acid(2)杂种(3-7)与分子杂交的结构合成并合成。然后在体外评估它们在LPS诱导的RAG-264.7巨噬细胞中产生的氧化氮(NO)产生的抑制作用和前列腺素(PG)合成调节基因的表达水平。发现所有混合物都没有显着的没有生产抑制电位,IC50值在27.69°θ≤3.06和40.19?±5.52?μm,没有显着的细胞毒性(CC50?≥≤100≤μm),除了6.比较抑制作用,细胞毒性和体外疗效指数(IEI),4(IC50 = 32.09?±4.04?μm; IEI = 6.23)和7(IC50 = 27.69?±3.06?μm; IEI = 6.40)比其他杂交种更适合以及他们的母体化合物eh和ma。通过减少的微粒体前列腺素E合酶-1表达和未改变的家务用COX-1表达,通过杂种4和7治疗进一步使该结果进一步统一。完全是,我们的调查结果表示混合动力车4和7可作为继续调查更有效的抗炎药物的平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号